Opportunistic Infections Therapy
New opportunistic infections therapy research from University of British Columbia, Department of Medicine discussed
Published in AIDS Weekly, May 3rd, 2010
Research findings, 'A mutation in Mycobacterium tuberculosis rpoB gene confers rifampin resistance in three HIV-TB cases,' are discussed in a new report. According to recent research from Vancouver, Canada, "Rifampin is a key component of standard short-course first-line therapy against Mycobacterium tuberculosis (MTB). Rifampin monoresistant MTB, previously a rare phenomenon, is now being reported at increasing rates worldwide."
"We report a mutation in the rpoB region leading to low level rifampin monoresistance in a cluster of HIV-positive patients. All rifampin monoresistant isolates identified from 2004 to 2006 underwent susceptibility confirmation,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2010-05-03)
More Articles from AIDS Weekly
- Research
Researchers identify the source of 'noise' in HIV - Anxiety Disorders
New anxiety disorders research from A. Fernandez et al outlined - Hepatitis B Virus
Research on hepatitis B virus reported by scientists at University of Alberta - Highly Active Antiretroviral Therapy
Research in the area of highly active antiretroviral therapy reported from University of Pretoria - HIV/AIDS
Investigators at University of Dusseldorf release new data on HIV/AIDS - HIV/AIDS
New HIV/AIDS research from Karolinska University described - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
